|
1
|
Bamias A and Dimopoulos MA: Angiogenesis
in human cancer: implications in cancer therapy. Eur J Intern Med.
14:459–469. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zetter BR: Angiogenesis and tumor
metastasis. Annu Rev Med. 49:407–424. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
He K, Jin K, Wang H and Teng L:
Anti-angiogenic therapy for colorectal cancer: on the way to
getting better! Hepatogastroenterology. 59:1113–1117.
2012.PubMed/NCBI
|
|
4
|
Das M and Wakelee H: Targeting VEGF in
lung cancer. Expert Opin Ther Targets. 16:395–406. 2012. View Article : Google Scholar
|
|
5
|
Teghom C, Giraud P, Menei P, et al: Renal
carcinoma: point on treatment of brain metastasis. Bull Cancer.
99:627–634. 2012.(In French).
|
|
6
|
Wicki A and Rochlitz C: Targeted therapies
in breast cancer. Swiss Med Wkly. 142:w135502012.
|
|
7
|
Dachs GU and Tozer GM: Hypoxia modulated
gene expression: angiogenesis, metastasis and therapeutic
exploitation. Eur J Cancer. 36:1649–1660. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fang XC and Yu BY: Application of
pyrolysis-high-resolution gas chromatography-pattern recognition to
the identification of the Chinese traditional medicine mai dong. J
Chromatogr. 514:287–292. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang PMAX: The initial research on Hupeh
Liriope Root Tuber inducing HL60 cell differentiation. Dalian Med
College J. 14:37–41. 1992.
|
|
10
|
Mimaki Y, Takaashi Y, Kuroda M, Sashida Y
and Nikaido T: Steroidal saponins from Nolina recurvata
stems and their inhibitory activity on cyclic AMP
phosphodiesterase. Phytochemistry. 42:1609–1615. 1996.
|
|
11
|
Jeong A, Lee HJ, Jeong SJ, Lee EO, Bae H
and Kim SH: Compound K inhibits basic fibroblast growth
factor-induced angiogenesis via regulation of p38 mitogen activated
protein kinase and AKT in human umbilical vein endothelial cells.
Biol Pharm Bull. 33:945–950. 2010. View Article : Google Scholar
|
|
12
|
Tong Y, Zhang X, Tian F, et al:
Philinopside A, a novel marine-derived compound possessing dual
anti-angiogenic and anti-tumor effects. Int J Cancer. 114:843–853.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun L, Lin S, Zhao R, Yu B, Yuan S and
Zhang L: The saponin monomer of dwarf lilyturf tuber, DT-13,
reduces human breast cancer cell adhesion and migration during
hypoxia via regulation of tissue factor. Biol Pharm Bull.
33:1192–1198. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang Y, Liu J, Kou J, Yu J and Yu B:
DT-13 suppresses MDA-MB-435 cell adhesion and invasion by
inhibiting MMP-2/9 via the p38 MAPK pathway. Mol Med Rep.
6:1121–1125. 2012.PubMed/NCBI
|
|
15
|
Jaffe EANR, Becker CG and Minick CR:
Culture of human endothelial cells derived from umbilical veins.
Identification by morphologic and immunologic criteria. J Clin
Invest. 52:2745–2756. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin S, Sun L, Hu J, et al: Chemokine C-X-C
motif receptor 6 contributes to cell migration during hypoxia.
Cancer Lett. 279:108–117. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee OH, Kim YM, Lee YM, et al: Sphingosine
1-phosphate induces angiogenesis: its angiogenic action and
signaling mechanism in human umbilical vein endothelial cells.
Biochem Biophys Res Commun. 264:743–750. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ashton AW, Yokota R, John G, et al:
Inhibition of endothelial cell migration, intercellular
communication, and vascular tube formation by thromboxane A(2). J
Biol Chem. 274:35562–35570. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen L, Endler A and Shibasaki F: Hypoxia
and angiogenesis: regulation of hypoxia-inducible factors via novel
binding factors. Exp Mol Med. 41:849–857. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wahl O, Oswald M, Tretzel L, Herres E,
Arend J and Efferth T: Inhibition of tumor angiogenesis by
antibodies, synthetic small molecules and natural products. Curr
Med Chem. 18:3136–3155. 2011. View Article : Google Scholar
|
|
21
|
Ma J and Waxman DJ: Combination of
antiangiogenesis with chemotherapy for more effective cancer
treatment. Mol Cancer Ther. 7:3670–3684. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Higa GM and Abraham J: Biological
mechanisms of bevacizumab-associated adverse events. Expert Rev
Anticancer Ther. 9:999–1007. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen HX and Cleck JN: Adverse effects of
anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol.
6:465–477. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chakrabarti S, Rizvi M, Pathak D, Kirber
MT and Freedman JE: Hypoxia influences CD40-CD40L mediated
inflammation in endothelial and monocytic cells. Immunol Lett.
122:170–184. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sluimer JC and Daemen MJ: Novel concepts
in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J
Pathol. 218:7–29. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Izzard AS, Emerson M, Prehar S, et al: The
cardiovascular phenotype of a mouse model of acromegaly. Growth
Horm IGF Res. 19:413–419. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Verlohren S, Stepan H and Dechend R:
Angiogenic growth factors in the diagnosis and prediction of
pre-eclampsia. Clin Sci. 122:43–52. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nagamatsu T, Fujii T, Kusumi M, et al:
Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1
expression under reduced oxygen: an implication for the placental
vascular development and the pathophysiology of preeclampsia.
Endocrinology. 145:4838–4845. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Forsythe JA, Jiang BH, Iyer NV, et al:
Activation of vascular endothelial growth factor gene transcription
by hypoxia-inducible factor 1. Mol Cell Biol. 16:4604–4613.
1996.PubMed/NCBI
|
|
30
|
Takahashi S: Vascular endothelial growth
factor (VEGF), VEGF receptors and their inhibitors for
antiangiogenic tumor therapy. Biol Pharm Bull. 34:1785–1788. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shalaby F, Rossant J, Yamaguchi TP, et al:
Failure of blood-island formation and vasculogenesis in
Flk-1-deficient mice. Nature. 376:62–66. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zachary I and Gliki G: Signaling
transduction mechanisms mediating biological actions of the
vascular endothelial growth factor family. Cardiovasc Res.
49:568–581. 2001. View Article : Google Scholar
|
|
33
|
Gerber HP, McMurtrey A, Kowalski J, et al:
Vascular endothelial growth factor regulates endothelial cell
survival through the phosphatidylinositol 3′-kinase/Akt signal
transduction pathway. Requirement for Flk-1/KDR activation. J Biol
Chem. 273:30336–30343. 1998.
|
